Alcoholism is a difficult addiction to overcome. Alcoholics Anonymous and other similar support groups wouldn’t exist if heavy drinkers could just give up the bottle any time they wanted, like so many of them stereotypically claim. With the help of a new kind of implant, however, this might finally be possible. Unfortunately, it also comes with a rather nightmarish privacy issue.
Very few people, if any actually enjoy being watched or monitored 24/7, but that is what an alcoholic patient would be signing up for if they decided to use an implant made by University of California San Diego (UCSD) researchers. This one cubic millimeter biosensor will act as something of an ankle bracelet. Only, instead of beeping when the wearer exits a designated area, it goes nuts when it detects alcohol.
As the project’s lead researcher Drew Hall said in a press release, the whole point to the implant is to help alcoholics develop a routine that they will stick to. It would certainly be difficult to fool people into thinking that a person has given up drinking if there’s a literal tattletale inside them all the time.
“The ultimate goal of this work is to develop a routine, unobtrusive alcohol and drug monitoring device for patients in substance abuse treatment programs,” Hall said.
While it may be potentially effective, perhaps the most effective method conceived so far, it’s also incredibly intrusive. As Futurism points out, this isn’t like the breathalyzer or blood tests that addicts would often have to contend with. It’s about having a monitor inside of them that will keep watch over them at all hours of the day.
What’s more, it seems even the researchers don’t know as much about the implant as they really should. The degree of difficulty in removing the implant, for example, is still in question.


FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 



